PHARMACOKINETICS OF SIFALIMUMAB AND TARGET MODULATION OF A TYPE I INTERFERON GENE SIGNATURE IN PATIENTS WITH MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS

被引：1
|
作者：
Morehouse, C. [1 ]
Brohawn, P. [1 ]
Higgs, B. [1 ]
Zheng, B. [1 ]
Yao, Y. [1 ]
Roskos, L. [1 ]
Robbie, G. [1 ]
机构：
[1] MedImmune LLC, Gaithersburg, MD USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2015年 / 74卷
关键词：
D O I：
10.1136/annrheumdis-2015-eular.4529
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0167
引用
收藏
页码：946 / 946
页数：1
相关论文
共 50 条
  • [1] Target Modulation of a Type I Interferon Gene Signature and Pharmacokinetics of Anifrolumab in a Phase IIb Study of Patients with Moderate to Severe Systemic Lupus Erythematosus
    Brohawn, Philip
    Santiago, Lingning
    Morehouse, Chris
    Higgs, Brandon
    Illei, Gabor
    Ranade, Koustubh
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [2] Target Modulation of a Type I Interferon (IFN) Gene Signature with Sifalimumab or Anifrolumab in Systemic Lupus Erythematosus (SLE) Patients in Two Open Label Phase 2 Japanese Trials
    Morehouse, Chris
    Chang, Linda
    Wang, Liangwei
    Brohawn, Philip
    Ueda, Shinya
    Illei, Gabor
    Greth, Warren
    Yoo, Stephen
    Roskos, Lorin
    Yao, Yihong
    Robbie, Gabriel
    Higgs, Brandon W.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S313 - S314
  • [3] Type I Interferon Signature in Systemic Lupus Erythematosus
    Bezalel, Shira
    Guri, Keren Mahlab
    Elbirt, Daniel
    Asher, Ilan
    Sthoeger, Zev Moshe
    [J]. ISRAEL MEDICAL ASSOCIATION JOURNAL, 2014, 16 (04): : 246 - 249
  • [4] Population Pharmacokinetics of Sifalimumab, An Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus Patients
    Narwal, Rajesh
    Roskos, Lorin
    White, Wendy
    Greth, Warren
    Robbie, Gabriel
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S546 - S546
  • [5] The Effect of Geography on the Efficacy of Sifalimumab, an Anti-Interferon-Alpha Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus
    Khamashta, M.
    Illei, G.
    Drappa, J.
    Wang, L.
    Greth, W.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (03) : S40 - S41
  • [6] THE EFFECT OF GEOGRAPHY ON THE EFFICACY OF SIFALIMUMAB, AN ANTI-INTERFERON-ALPHA MONOCLONAL ANTIBODY, IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS
    Khamashta, M.
    Illei, G.
    Drappa, J.
    Wang, L.
    Greth, W.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 951 - 952
  • [7] Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus
    Rajesh Narwal
    Lorin K. Roskos
    Gabriel J. Robbie
    [J]. Clinical Pharmacokinetics, 2013, 52 : 1017 - 1027
  • [8] Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus
    Narwal, Rajesh
    Roskos, Lorin K.
    Robbie, Gabriel J.
    [J]. CLINICAL PHARMACOKINETICS, 2013, 52 (11) : 1017 - 1027
  • [9] Type I interferon in systemic lupus erythematosus
    Crow, M. K.
    [J]. INTERFERON: THE 50TH ANNIVERSARY, 2007, 316 : 359 - 386
  • [10] Type I Interferon and Systemic Lupus Erythematosus
    Elkon, Keith B.
    Stone, Vivian V.
    [J]. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2011, 31 (11): : 803 - 812
12345